Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by AIA Group Ltd

Key Points

• AIA Group Ltd increased its holdings in Gilead Sciences by 48.8% during Q1, now owning 22,219 shares worth approximately $2.49 million.
• Gilead's CFO recently sold 2,500 shares of the company's stock for $277,575, reflecting a 1.51% decrease in his position.
• Gilead Sciences has announced a quarterly dividend of $0.79 per share, with an annualized yield of 2.6%, payable on September 29th.

AIA Group Ltd grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 48.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,219 shares of the biopharmaceutical company's stock after purchasing an additional 7,286 shares during the period. AIA Group Ltd's holdings in Gilead Sciences were worth $2,490,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the first quarter worth about $25,000. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences in the first quarter worth approximately $29,000. Core Alternative Capital lifted its stake in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares in the last quarter. IMA Advisory Services Inc. bought a new position in shares of Gilead Sciences in the first quarter worth approximately $39,000. Finally, Clearstead Trust LLC raised its holdings in shares of Gilead Sciences by 287.6% during the first quarter. Clearstead Trust LLC now owns 376 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 279 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.9%

NASDAQ GILD traded down $1.12 during trading on Thursday, reaching $119.02. 5,461,007 shares of the company's stock traded hands, compared to its average volume of 8,364,447. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market cap of $147.68 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 0.75 and a beta of 0.33. The company's 50 day simple moving average is $111.59 and its two-hundred day simple moving average is $108.00. Gilead Sciences, Inc. has a 12-month low of $72.89 and a 12-month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at approximately $18,054,588.30. The trade was a 1.51% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,500 shares of company stock worth $8,734,625. Company insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Finally, Oppenheimer reduced their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Seven equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $114.82.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.